Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: A meta-analysis

Drugs

Volumn 68, Issue 17, 2008, Pages 2469-2481

  Athanassa, Zoe ^a   Makris, Gregory ^a   Dimopoulos, George ^a,b   Falagas, Matthew E ^a,c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibacterials, therapeutic use; Community acquired pneumonia, treatment; Oral; Switch therapy

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CEFACLOR; CEFALEXIN; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CEFUROXIME; CEFUROXIME AXETIL; CLARITHROMYCIN; CLAVULANIC ACID; ERYTHROMYCIN; LEVOFLOXACIN;

ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; META ANALYSIS; MORTALITY; PHLEBITIS; RASH; RECURRENT DISEASE; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; INPATIENTS; LENGTH OF STAY; PNEUMONIA, BACTERIAL;

EID: 56549088575     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/0003495-200868170-00005     Document Type: Article

References (27)

1. Marston BJ, Plouffe JF, File Jr TM, et al. Incidence of community-acquired pneumonnia requiring hospitalization: results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997; 157: 1709-18
2. Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the United Kingdom. Eur Respir J 1997; 10: 1530-4
3. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-37
4. Rello J, Catalan M, Diaz E, et al. Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 2002; 28: 1030-5
5. Feikin DR, Schuchat A, Kokzak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90: 223-9
6. Mandell LA, Wunderink RG, Anzueto A, et al., for the Infectious Diseases Society of America - American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27-72
7. Woodhead M, Blasi F, Ewig S, et al. ERS task force in collaboration with ESCMID. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-80
8. Castro-Guardiola A, Viejo-Rodriguez AL, Soler-Simon S, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med 2001; 111: 367-74
9. Siegel RE, Halpem NA, Almenoff PL, et al. A prospective randomized study of inpatient IV antibiotics for community-acquired pneumonia: the optimal duration of therapy. Chest 1996; 110: 965-71
10. Rhew DC, Tu GS, Ofman J, et al. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med 2001; 161: 722-7
11. Halm EA, Switzer GE, Mittman BS, et al. What factors influence physicians' decision to switch from intravenous to oral antibiotics for community-acquired pneumonia? J Gen Intern Med 2001; 16: 599-605
12. Moher D, Pham B, Jones A, et al. Does quality of reports of randomized trials affects estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-13
13. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50
14. Lim WS, van der Eerden MM, Laing R, et al. Defining community-acquired pneumonia on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-82
15. Yaqub A, Khan Z. Comparison of early intravenous to oral switch amoxicillin/clavulanate with parenteral ceftriaxone in treatment of hospitalized patients with community acquired pneumonia. Pak J Med Sci 2005; 21: 259-66
16. Oosterheert JJ, Bonten MJM, Schneider MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community-acquired pneumonia: multicentre randomized trial. BMJ 2006; 333: 1193-8
17. Omidvari K, de Boisblanc BP, Karam G, et al. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998; 92: 1032-9
18. Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998; 30: 397-404
19. Lee RWW, Lindstrom ST. Early switch to oral antibiotics and early discharge guidelines in the management of patients with community-acquired pneumonia. Respirology 2007; 12: 111-6
20. Capelategui A, Espana PP, Quintana JM, et al. Improvement of process of care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before and after design study. CID 2004; 39: 995-63
21. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000; 283: 749-55
22. Halm EA, Fine MJ, Kapoor WN, et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002; 162: 1278-84
23. Kothe H, Bauer T, Marre R, et al. Outcome of CAP: influence of age, residence status, and antimicrobial treatment. Eur Respir J 2008; 32: 139-46
24. Polic-Vizintin M, Lepee M, Stimac D, et al. Risk of pneumonia reccurence in patients previously hospitalized for pneumonia: a retrospective study. Coll Antropol 2005; 29: 213-9
25. Hedlund J, Ortqvist AB, Kalin M, et al. Risk of pneumonia in patients previously treated in hospital for pneumonia. Lancet 1992; 340: 396-7
26. Lanbeck P, Odenholt I, Riesbeck K. Dicloxacillin and erythromycin at high concentrations increase ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis. J Antimicrob Chemother 2004; 53: 174-9
27. Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: results from the pneumonia patient outcome research team cohort study. Arch Intern Med 2002; 162: 1059-64